Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolamba (AIC) for ragweed-induced asthma
NCT00318747Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2006
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate in asthma, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Change in average daily asthma medication use. Started Apr 2006; status: terminated.
02
Drugs
amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00318747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318747.